Zenith TX2 pivotal study, TX2 postapproval study, Zenith Alpha Thoracic study, TRANSFIX study, and STABLE I study. Primary outcomes of this post hoc analysis include 30-day and 1-year mortality and morbidity, and cumulative mortality and reinterventions. Cox regression analyses were performed to identify risk factors for mortality and reinterventions.
heart failure (HR, 2.87), serum creatinine (HR. 1.19 per 1 mg/dL), iliac tortuosity (HR, 1.32), and blood transfusion (HR 1.59 per 500 mL packed red blood cells [PRBC] ); and 30-day stroke (HR, 3.93) , paraplegia (HR, 7.79), and paraparesis (HR, 2.46) as significant predictors for all-cause mortality. Patients treated for dissection, but not TAA or BTAI, demonstrated significantly higher risk for reintervention (acute TBAD HR, 5.65; nonacute TBAD HR, 6.60) as compared to patients treated for thoracic ulcers (reference group). Intraoperative contrast (HR. 1.31 per 100 mL) and blood transfusion volumes (HR, 1.42 per 500 mL PRBC), surrogates of case complexity, were also significant predictors for reintervention.
Conclusions: For patients treated in accordance with the IFU, the 30-day results of TEVAR within these clinical trials demonstrate exceptionally low mortality and stroke rates. Acute and nonacute TBAD are associated with a higher risk for reintervention, possibly attributed to the natural history of the disease, while age, reduced cardiac and renal functions, complex access, intraoperative transfusion, and early neurologic complications after TEVAR are associated with higher cumulative mortality. Follow-up, mean 6 SD, years 4.0 6 1.8 3.8 6 1.9 2.0 6 1.2 3.0 6 1.7 3.1 6 1.5 3.1 6 1.7
30-day, % (n/N) Objectives: The appropriateness of endovascular abdominal aortic repair (EVAR) of uncomplicated abdominal aortic aneurysm (AAA) is dependent on the risk/benefit ratio, particularly in patients aged >80 years with possible short life expectancy. The aim of this study was to evaluate the survival of patients aged >80 years after EVAR and analyze predictors of late mortality in order to analyze the efficacy of the EVAR treatment in these patients.
Methods: A prospective evaluation of patients aged >80 years treated by nonurgent EVAR, from 2006 to 2015, was performed. Thirty-day mortality and long-term survival were evaluated, and independent risk factors for mortality were investigated by multivariate logistic and Cox analysis.
Results: In 8eyear period, 201 of 1135 EVARs (16%) were performed in patients aged >80 years. The mean age was 84 6 2 years (min: 81, max: 100), 84% were male, and the mean AAA diameter was 61 6 8 mm. Thirty-four patients (16%) had American Society of Anesthesiologist (ASA) score of IV. Overall 30-day mortality was 2%, and was significantly greater in ASA IV compared with ASA <IV (9.4% vs 0.6%; P ¼ .04) as confirmed also by multivariate analysis (odds ratio [OR], 12.7; 95% confidence interval [CI], 1.1-141.8). The mean follow-up was 36 6 18 months, and overall survival at 1, 2, 3, and 5 years was 88% 6 2%, 84% 6 3%, 79% 6 3%, and 56% 6 5%, respectively. At the multivariate Cox regression ASA IV and peripheral artery obstructive disease (PAOD) were the only independent predictors for midterm mortality (hazard ratio, 2.0; 95% CI, 1.01-3.90, P ¼ .04; and hazard ratio, 2.3; 95% CI, 1.02-5.3, P ¼ .04, respectively). The 2-year survival was significantly influenced by the presence of both (ASA IV and PAOD), one (ASA IV or PAOD), or any of the two risk factors: 33% 6 27%, 68% 6 8%, and 93 6 3%, respectively (P ¼ .02). Only patients with one or no risk factors reached the 5-year follow-up.
Conclusions: EVAR in patients aged >80 years is associated with an overall low perioperative mortality rate, particularly in ASA <IV patients (0.6%). The survival of patients with none or just one risk factor can be as high as 90% at 2 years, thus justifying the AAA treatment. On the other hand, EVAR treatment could be justified only in cases of impending AAA rupture in with ASA IV and PAOD, since perioperative results and life expectancy is significantly poorer in this setting.
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FT02.
Standard Objectives: This study was performed to assess immediate and midterm outcomes for urgent and elective patients with thoracoabdominal aortic aneurysms (TAAAs) treated with the first off-the-shelf multibranched endograft (Zenith t-Branch; Cook Medical, Bloomington, Ind) for multibranched endovascular aneurysm repair (mbEVAR), with a single step or a staged surgical approach. Results: The elective and urgency/emergency groups did not differ significantly except for aneurysm measurements: urgent/emergent appeared to have smaller proximal diameter (P ¼ .001) and larger maximum diameter (P ¼ .04). Technical success rate was 97% (n ¼ 71 of 73; 2 asymptomatic celiac trunk occlusion before bridging [staged approach]). The 30-day mortality was 3% (n ¼ 2, myocardial infarctions; 
